Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Gefitinib in Resectable HCC
NCT00282100Phase 2Unknown
- Sponsor
- Tan Tock Seng Hospital
- Start
- Dec 2005
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gefitinib in hepatocellular carcinoma (HCC), sponsored by Tan Tock Seng Hospital. Primary endpoint: Genetic or protein markers at 2 years. Status: unknown.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00282100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00282100.